Transaction in Own Shares

2009-11-23 15:03:02 -

BAGSVAERD, DENMARK -- (Marketwire) -- 11/23/09 -- Novo Nordisk A/S - Share repurchase programme

On 7 August 2009 Novo Nordisk initiated its share repurchase programme in accordance with the provisions of the European Commission's regulation no 2273/2003 of 22 December 2003, also referred to as the Safe Harbour rules.

Under the programme Novo Nordisk will repurchase B shares for an amount up to DKK 2.4 billion in the period from 10 August 2009 to 18 December 2009.

Since the announcement as of 16 November 2009, the following transactions have been made under the programme:





                          Number of    Average     Transaction value,

                           shares   purchase price        DKK

Accumulated, last

announcement              5,464,099                     1,746,802,641

16 November 2009             70,000       328.7680         23,013,760

17 November 2009             61,500       327.3010         20,129,012

18 November 2009             70,000       329.2998         23,050,986

19 November 2009             68,000       329.5300         22,408,040

20 November 2009             60,000       330.7910         19,847,460

Accumulated under the

programme                 5,793,599                     1,855,251,898

With the transactions stated above, Novo Nordisk owns a total of 30,509,977 treasury shares, corresponding to 4.9% of the share capital. The total amount of shares in the company is 620,000,000 including treasury shares.

Novo Nordisk is a healthcare company and a world leader in diabetes care. In addition, Novo Nordisk has a leading position within areas such as haemostasis management, growth hormone therapy and hormone replacement therapy. Novo Nordisk manufactures and markets pharmaceutical products and services that make a significant difference to patients, the medical profession and society. With headquarters in Denmark, Novo Nordisk employs more than 29,000 employees in 81 countries, and markets its products in 179 countries.
Novo Nordisk's B shares are listed on the stock exchanges in Copenhagen and London. Its ADRs are listed on the New York Stock Exchange under the symbol 'NVO'. For more information, visit novonordisk.com.



Further information:



Media:                 Investors:



Elin K Hansen          Mads Veggerby Lausten

Tel: (+45) 4442 3450   Tel: (+45) 4443 7919

 ekh@novonordisk.com : mailto:ekh@novonordisk.com      mlau@novonordisk.com : mailto:mlau@novonordisk.com 



                       Kasper Roseeuw Poulsen

                       Tel: (+45) 4442 4471

                        krop@novonordisk.com : mailto:krop@novonordisk.com 



In North America:      In North America:

Sean Clements          Hans Rommer

Tel: (+1) 609 514 8316 Tel: (+1) 609 919 7937

 secl@novonordisk.com : mailto:secl@novonordisk.com     hrmm@novonordisk.com : mailto:hrmm@novonordisk.com

Company Announcement no 69 / 2009

This announcement was originally distributed by Hugin. The issuer is solely responsible for the content of this announcement.

Copyright © Hugin AS 2009. All rights reserved.